ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (

ORIC oric® Pharmaceuticals announces initiation of himalayas-1 phase 3 trial in mcrpc evaluating rinzimetostat in combination with nubeqa® (darolutamide), supported by clinical collaboration with Bayer